Close Menu

NEW YORK – Sphingotec announced its in vitro diagnostic assay for dipeptidyl peptidase 3 has been CE-IVD marked.

The company has launched the test.

According to the German diagnostic company, the assay, called IB10 Sphingotec DPP3, is the first CE-IVD-marked point-of-care biomarker test that can quantify DPP3 blood plasma levels. DPP3 is a biomarker that can predict outcomes in patients with cardiogenic shock when they are admitted to hospital intensive care units.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

May
10
Sponsored by
MeMed

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

May
13
Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.